RTW Investments LP grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 5.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,495,143 shares of the biopharmaceutical company’s stock after acquiring an additional 190,929 shares during the quarter. PTC Therapeutics comprises approximately 12.2% of RTW Investments LP’s investment portfolio, making the stock its 2nd largest holding. RTW Investments LP owned about 8.42% of PTC Therapeutics worth $69,938,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. Macquarie Group Ltd. acquired a new position in PTC Therapeutics in the 3rd quarter worth approximately $102,000. Nisa Investment Advisors LLC acquired a new position in PTC Therapeutics in the 2nd quarter worth approximately $125,000. Public Employees Retirement System of Ohio acquired a new position in PTC Therapeutics in the 2nd quarter worth approximately $142,000. Quantbot Technologies LP acquired a new position in PTC Therapeutics in the 3rd quarter worth approximately $150,000. Finally, Prudential Financial Inc. acquired a new position in PTC Therapeutics in the 2nd quarter worth approximately $201,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.
Shares of PTC Therapeutics, Inc. (NASDAQ PTCT) opened at $15.97 on Wednesday. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98. PTC Therapeutics, Inc. has a 52-week low of $8.12 and a 52-week high of $22.00.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).
Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.